Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] License And Collaboration Agreements [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Potential commercial milestone payments under agreement PotentialCommercialMilestonePaymentsUnderAgreement Income Statement [Abstract] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Additional Paid-In Capital Additional Paid-in Capital [Member] Document Fiscal Period Focus Document Fiscal Period Focus Intrinsic value of options exercised Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value Cost of product sales Cost of Goods and Services Sold Diluted weighted average common shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Diluted Schedule of Inventory Schedule of Inventory, Current [Table Text Block] Expected term (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Potential proceeds from royalties (percent) ProceedsfromRoyaltiesPercent Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-Sale [Line Items] NIAID NationalInstituteOfAllergyAndInfectiousDiseasesMember Marketable securities Investments Fair Value of Financial Instruments Fair Value of Financial Instruments, Policy [Policy Text Block] Common stock, $0.01 par value -- 125,000,000 shares authorized, 61,462,189 and 61,307,428 shares outstanding at September 30, 2022 and December 31, 2021, respectively Common Stock, Value, Issued Non-refundable upfront payment, net of tax withholding Nonrefundable Upfront Fees, Net Of Tax Withholding Nonrefundable Upfront Fees, Net Of Tax Withholding Financial Instruments [Domain] Financial Instruments [Domain] Granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Range [Domain] Statistical Measurement [Domain] Shares, Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Aggregate Intrinsic Value, Exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Share-Based Payment Arrangement [Abstract] Stock plan related activity Shares Granted, Value, Share-Based Payment Arrangement, after Forfeiture Additional paid-in capital Additional Paid in Capital, Common Stock Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Incyte MGA012 Supply Agreement Incyte MGA012 Supply Agreement [Member] Incyte MGA012 Supply Agreement Other non-cash items Other Noncash Income (Expense) Incyte MGA012 Agreement IncyteMGA012AgreementMember Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Current liabilities: Liabilities, Current [Abstract] Cash received for options exercised Proceeds from Stock Options Exercised Other non current liabilities Increase (Decrease) in Other Current Liabilities Weighted- Average Remaining Contractual Term, Vested and expected to vest (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Net loss Net loss Net loss Net Income (Loss) Attributable to Parent Deferred revenue Deferred revenue, current Contract with Customer, Liability, Current Property, equipment and software included in accounts payable or accruals Capital Expenditures Incurred but Not yet Paid Subsequent Event Type [Axis] Subsequent Event Type [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Equity Component [Domain] Equity Component [Domain] Amendment Flag Amendment Flag Net cash provided by (used in) investing activities Net Cash Provided by (Used in) Investing Activities Subsequent Event Type [Domain] Subsequent Event Type [Domain] Scenario [Axis] Scenario [Axis] Accumulated other comprehensive loss AOCI, Debt Securities, Available-for-Sale, Adjustment, after Tax Total assets measured at fair value Assets, Fair Value Disclosure Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent RevenuesFromCMOAgreementsMember RevenuesFromCMOAgreementsMember [Member] RevenuesFromCMOAgreementsMember Plan Name [Axis] Plan Name [Axis] Gross Unrealized Gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Entity Current Reporting Status Entity Current Reporting Status Other non current assets Other Assets, Noncurrent Securities Fair Value Debt Securities, Available-for-Sale Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract] Shares, Exercisable (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Non-refundable upfront payment NonRefundableUpfrontFees Supplemental Cash Flow Information [Abstract] Supplemental Cash Flow Information [Abstract] Weighted- Average Exercise Price, Forfeited (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Depreciation and amortization expense Depreciation, Depletion and Amortization Purchase price of common stock percent of the fair market value Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent Milestones Value Added Tax Milestones Value Added Tax Milestones Value Added Tax Total unrecognized compensation cost Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Plan Name [Domain] Plan Name [Domain] Target nomination, option fees and milestone Target nomination, option fees and milestone Target,nomination, option fees and milestone Statement of Cash Flows [Abstract] Entity Address, State or Province Entity Address, State or Province Level 1 Fair Value, Inputs, Level 1 [Member] Counterparty Name [Axis] Counterparty Name [Axis] Weighted- Average Remaining Contractual Term, Outstanding (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Options outstanding (in shares) Shares, Outstanding, Beginning Balance (in shares) Shares, Outstanding, Ending Balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Award Type [Axis] Award Type [Axis] Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Proceeds from stock option exercises and ESPP Purchases ProceedsfromStockOptionsExercisedAndESPPPurchases Janssen Biotech Inc Janssen Biotech Inc [Member] Janssen Biotech Inc Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Lease liabilities Operating Lease, Liability, Current Collaboration And Other Agreements [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Property, equipment and software, net Property, Plant and Equipment, Net Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Incyte MGA012 Agreement - Clinical activities IncyteMGA012AgreementClinicalActivitiesMember Maximum amount available for issuance Common Stock, Maximum Amount Available For Issuance Common Stock, Maximum Amount Available For Issuance Schedule of RSU Activity Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block] Available-for-sale Marketable Securities Debt Securities, Available-for-Sale [Table Text Block] Incyte MGA012 Clinical Services Incyte MGA012 Clinical Services [Member] Incyte MGA012 Clinical Services Costs and expenses: Costs and Expenses [Abstract] Expected volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Shares, Forfeited or expired (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Forfeited or expired (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Other income Other Nonoperating Income (Expense) Unrealized gain (loss) on investments OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax Sales of stock purchase price (in dollars per share) Sale of Stock, Price Per Share Stock plan activity (in shares) Stock Issued During Period Shares Stock Plan Activity Number of shares issued due to stock plan related activity. Common stock, shares authorized (in shares) Common Stock, Shares Authorized Total liabilities Liabilities Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Maximum Maximum [Member] Cash flows from investing activities Net Cash Provided by (Used in) Investing Activities [Abstract] Issuance of common stock, net of offering costs Stock Issued During Period, Value, New Issues Potential development and regulatory milestone payments under agreement PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Contract Manufacturing Contract Manufacturing [Member] Contract Manufacturing Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Work in process Inventory, Work in Process, Gross At the Market Offering At The Market Offering [Member] At The Market Offering Deferred revenue Increase (Decrease) in Contract with Customer, Liability Total current assets Assets, Current 2022 Gilead Collaboration And License Agreement 2022 Gilead Collaboration And License Agreement [Member] 2022 Gilead Collaboration And License Agreement Document Type Document Type Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Weighted- Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Entity Small Business Entity Small Business Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Fair Value, Measurement Frequency [Domain] Measurement Frequency [Domain] Stockholders' Equity Stockholders' Equity Note Disclosure [Text Block] Common stock purchased (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period Premium received on stock purchase PremiumReceivedOnStockPurchase PremiumReceivedOnStockPurchase Nonrefundable payment tax withholding Nonrefundable Payment Tax Withholding Nonrefundable Payment Tax Withholding Revenues: Revenues [Abstract] Assets: Assets, Fair Value Disclosure [Abstract] Beginning Balance (in dollars per share) Ending Balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Purchases of marketable securities Payments to Acquire Debt Securities, Available-for-Sale Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Product and Service [Domain] Product and Service [Domain] Unrecognized compensation expense related to non-vested stock-options, net of related forfeiture estimates Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Entity Shell Company Entity Shell Company Gilead Gilead [Member] Gilead Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] RevenuesFromCMOAmendmentAgreement RevenuesFromCMOAmendmentAgreement [Member] RevenuesFromCMOAmendmentAgreement Accrued expenses and other current liabilities Increase (Decrease) in Accrued Liabilities Offering period Share-Based Compensation Arrangement By Share-based Payment Award, Offering Period Share-Based Compensation Arrangement By Share-based Payment Award, Offering Period Aggregate Intrinsic Value, Outstanding, Ending Balance Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Estimated variable consideration Revenue, Information Used To Assess Variable Consideration, Amount Revenue, Information Used To Assess Variable Consideration, Amount Financial Instrument [Axis] Financial Instrument [Axis] Accounts receivable Increase (Decrease) in Accounts Receivable Title of 12(b) Security Title of 12(b) Security Subsequent Event Subsequent Event [Member] Collaborative and other agreements RevenueFromCollaborativeAgreementsMember Zai Lab Clinical Supply Agreements Zai Lab Clinical Supply Agreements [Member] Zai Lab Clinical Supply Agreements Document Period End Date Document Period End Date Total costs and expenses Costs and Expenses Zai Lab Agreement, TRIDENT molecule Zai Labs Collaboration And License Agreement, TRIDENT molecule [Member] Zai Labs Collaboration And License Agreement, TRIDENT molecule Subsequent Event [Line Items] Subsequent Event [Line Items] Shares, Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures Class of Stock [Line Items] Class of Stock [Line Items] Total assets Assets Cost of manufacturing services Cost of manufacturing services Cost of manufacturing services Amortization of premiums and discounts on marketable securities Accretion (Amortization) of Discounts and Premiums, Investments Investments, Debt and Equity Securities [Abstract] Income Statement Location [Axis] Income Statement Location [Axis] Financial Assets Measured at Fair Value on a Recurring Basis Fair Value Measurements, Recurring and Nonrecurring [Table Text Block] Revenue Collaboration And Other Agreements Disclosure [Text Block] Liabilities and stockholders' equity Liabilities and Equity [Abstract] Beginning balance (in shares) Ending balance (in shares) Shares, Issued Accrued expenses and other current liabilities Accrued Liabilities, Current U.S. Treasury securities US Treasury Securities [Member] Weighted- Average Exercise Price, Granted (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Weighted- Average Exercise Price, Exercised (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Accounting Policies [Abstract] I-Mab Biopharma Collaboration And License Agreement Clinical Supply I-Mab Biopharma Collaboration And License Agreement Clinical Supply [Member] I-Mab Biopharma Collaboration And License Agreement Clinical Supply Proceeds of stock sale Sale of Stock, Consideration Received on Transaction Inventory, net Total inventory, net Inventory, Net Development and regulatory milestones recognized Development And Regulatory Milestone Payments Under Agreement, Recognized Development And Regulatory Milestone Payments Under Agreement, Recognized Accounts payable Accounts Payable, Current Potential milestone payments and royalties on product sales Potential Milestone Payments and Royalties On Product Sales Potential Milestone Payments and Royalties On Product Sales Stockholders' equity: Stockholders' Equity Attributable to Parent [Abstract] Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Other non current assets Increase (Decrease) in Other Operating Assets Aggregate Intrinsic Value, Vested and expected to vest Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Zai Lab Agreement, Margetuximab Zai Labs Collaboration And License Agreement, Margetuximab [Member] Zai Labs Collaboration And License Agreement, Margetuximab Valuation Assumptions Using the Black-Scholes Option-Pricing Model Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Accounts payable Increase (Decrease) in Accounts Payable and Other Operating Liabilities Lease liabilities Increase (Decrease) in Operating Lease Liability Entity Filer Category Entity Filer Category Proceeds from issuance of common stock, net of offering costs Proceeds from Issuance of Common Stock Basic weighted average common shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Basic Award Type [Domain] Award Type [Domain] Fair value of shares vested Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value 2018 Zai Lab Agreement 2018 Zai Lab Collaboration And License Agreement [Member] 2018 Zai Lab Collaboration And License Agreement Unrecognized compensation expense recognition period (in years) Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition 2016 Employee Stock Purchase Plan TwoThousandSixteenEmployeeStockPurchasePlanMember Weighted- Average Remaining Contractual Term, Exercisable (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Finished goods Inventory, Finished Goods, Gross Stock-based compensation expense Share-Based Payment Arrangement, Expense Number of shares per employee Share-based Compensation Arrangement by Share-based Payment Award, Number Of Shares Received For Each Vested Award Share-based Compensation Arrangement by Share-based Payment Award, Number Of Shares Received For Each Vested Award Security Exchange Name Security Exchange Name Entity Registrant Name Entity Registrant Name Weighted-average exercise price of stock options outstanding (in dollars per share) Weighted- Average Exercise Price, Outstanding, Beginning Balance (in dollars per share) Weighted- Average Exercise Price, Outstanding, Ending Balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Issuance of common stock, net of offering costs (in shares) Number of shares issued or sold (in shares) Stock Issued During Period, Shares, New Issues One Time Millstone Credit One Time Millstone Credit One Time Millstone Credit Subsequent Events Subsequent Events [Text Block] Expected dividend yield Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Incyte Corporation IncyteCorporationMember General and Administrative General and Administrative Expense [Member] Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Entity Address, City or Town Entity Address, City or Town Cover [Abstract] Beginning balance Ending balance Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Revenues From Grants RevenuesFromGrantsMember Stock-Based Compensation Share-Based Payment Arrangement [Text Block] Asset Class [Domain] Asset Class [Domain] Potential annual increase in shares reserved for future issuance as percentage of outstanding share PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan Minimum Minimum [Member] Statement of Financial Position [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Payroll deduction percentage EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Forecast Forecast [Member] Risk-free interest rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Commitments and Contingencies Disclosure [Abstract] Janssen Collaboration and License Agreement Janssen Collaboration And License Agreement [Member] Janssen Collaboration And License Agreement Fair Value of Financial Instruments Fair Value Disclosures [Text Block] Taxes paid related to net share settlement of equity awards Payment, Tax Withholding, Share-Based Payment Arrangement Total liabilities and stockholders' equity Liabilities and Equity Trading Symbol Trading Symbol Entity File Number Entity File Number Deferred revenue, net of current portion Contract with Customer, Liability, Noncurrent Research and development Research and Development Expense Organization, Consolidation and Presentation of Financial Statements [Abstract] Annual Fixed Payments Total Annual Fixed Payments Total Annual Fixed Payments Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Level 2 Fair Value, Inputs, Level 2 [Member] Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Restricted Stock Units Restricted Stock Units (RSUs) [Member] Current Fiscal Year End Date Current Fiscal Year End Date Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised Diluted net loss per common share (in usd per share) Earnings Per Share, Diluted Shares, Vested and expected to vest (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Sale of Stock [Domain] Sale of Stock [Domain] Cash and cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Other comprehensive loss: Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Award vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period I-Mab I-Mab Biopharma [Member] I-Mab Biopharma Nature of Operations Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block] Share-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Number of commercialized molecules NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement Subsequent Events [Abstract] Revenues Revenues Total current liabilities Liabilities, Current Additional Payments Additional Annual Fixed Payments Additional Annual Fixed Payments Marketable Securities Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Debt Securities, Trading, and Equity Securities, FV-NI [Table] Debt Securities, Trading, and Equity Securities, FV-NI [Table] Basic net loss per common share (in usd per share) Earnings Per Share, Basic Corporate debt securities Corporate Debt Securities [Member] Entity Address, Address Line One Entity Address, Address Line One Counterparty Name [Domain] Counterparty Name [Domain] Deferred revenue Contract with Customer, Liability Total stockholders' equity Stockholders' Equity Attributable to Parent I-Mab Biopharma Collaboration and License Agreement I-Mab Biopharma Collaboration And License Agreement [Member] I-Mab Biopharma Collaboration And License Agreement Unrealized gain (loss) on investments Unrealized Gain (Loss) on Investments Product and Service [Axis] Product and Service [Axis] Forfeited or expired (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Allowance for credit loss related to available-for-sale debt securities Debt Securities, Available-for-Sale, Allowance for Credit Loss Fair Value Disclosures [Abstract] Schedule of Stock Options Roll Forward Schedule of Stock Options Roll Forward [Table Text Block] Entity Interactive Data Current Entity Interactive Data Current Number of shares sold (in shares) Sale of Stock, Number of Shares Issued in Transaction Proceeds from sale and maturities of marketable securities Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale Government-sponsored enterprises US Government-sponsored Enterprises Debt Securities [Member] Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Inventory valuation reserves Inventory Valuation Reserves Inventory, Net Inventory Disclosure [Text Block] Money market funds Money Market Funds [Member] Revenue From Performance of the Research and Development Activities Revenue From Performance Of The Research And Development Activities [Member] Revenue From Performance Of The Research And Development Activities Equity [Abstract] Accumulated Deficit Retained Earnings [Member] Subsequent Event [Table] Subsequent Event [Table] Inventory Disclosure [Abstract] Entity Tax Identification Number Entity Tax Identification Number Share-based compensation, number of shares authorized (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Collaborative agreement transaction price CollaborativeAgreementTransactionPrice Common Stock Common Stock [Member] Stock-Based Compensation Expense Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Stock plan related activity Stock Issued During Period Value Stock Plan Activity Value of shares issued due to stock plan related activity. Statement [Table] Statement [Table] Zai Labs Zai Lab [Member] Zai Lab Exercised (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Document Quarterly Report Document Quarterly Report Current assets: Assets, Current [Abstract] Lease liabilities, net of current portion Operating Lease, Liability, Noncurrent Range [Axis] Statistical Measurement [Axis] Revenues From License Agreements RevenuesFromLicenseAgreementsMember Government agreements RevenueFromGovernmentAgreementsMember Net change in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Accumulated deficit Retained Earnings (Accumulated Deficit) Accumulated Other Comprehensive Income (Loss) AOCI Including Portion Attributable to Noncontrolling Interest [Member] 2003 Stock Incentive Plan A2003StockIncentivePlanMember Accounts receivable Accounts Receivable, after Allowance for Credit Loss, Current Entity Central Index Key Entity Central Index Key Equity Components [Axis] Equity Components [Axis] Scenario [Domain] Scenario [Domain] Number of performance obligations Number Of Performance Obligations Measurement Frequency [Axis] Measurement Frequency [Axis] Weighted-Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Fair Value Measurements, Recurring Basis Fair Value, Recurring [Member] Weighted- Average Exercise Price, Exercisable (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Variable consideration recognized Clinical trial activities selling price amount Revenue, Multiple-Deliverable Arrangements, Determination Of Selling Price, Amount Revenue, Multiple-Deliverable Arrangements, Determination Of Selling Price, Amount Weighted- Average Exercise Price, Expired (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Document Fiscal Year Focus Document Fiscal Year Focus Cash flows from operating activities Net Cash Provided by (Used in) Operating Activities [Abstract] City Area Code City Area Code Selling, general and administrative General and Administrative Expense Statement [Line Items] Statement [Line Items] Assets Assets [Abstract] Beginning Balance (in shares) Ending Balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Total potential value TotalPotentialValueUnderAgreement 2021 Zai Lab Agreements 2021 Zai Lab Agreements [Member] 2021 Zai Lab Agreements Statement of Stockholders' Equity [Abstract] Sale of Stock [Axis] Sale of Stock [Axis] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Cash flows from financing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Gross Unrealized Losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Product sales, net Product [Member] Maximum amount available for issuance, increase Common Stock, Maximum Amount Available For Issuance, Increase Common Stock, Maximum Amount Available For Issuance, Increase Potential annual increase in shares reserved for future issuance (in shares) CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance Asset Class [Axis] Asset Class [Axis] Stock-based compensation Share-Based Payment Arrangement, Noncash Expense Weighted-average grant-date fair value of options granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Other non current liabilities Other Liabilities, Noncurrent Weighted- Average Exercise Price, Vested and expected to vest (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Document Transition Report Document Transition Report Local Phone Number Local Phone Number Stock Incentive Plan 2013 StockIncentivePlan2013Member Purchases of property, equipment and software Payments to Acquire Property, Plant, and Equipment Loss from operations Operating Income (Loss) Research and Development Research and Development Expense [Member] Inventory Increase (Decrease) in Inventories Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Collaboration and License Agreements [Abstract] Collaboration and License Agreements [Abstract] Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding